There’s been increasing discussion among scientists and activists, including among a terrific group of breast cancer activists and survivors (you can find them on Twitter by following the #BCSM hashtag) about the role of metastasis in breast and other cancers. In the past few years, this has become one of the most promising areas in the study of cancer. After all, it’s metastasis, when tumors spread to other parts of the body, that makes breast and other cancers deadly.
Now some groundbreaking work in this area has been recognized by our friends at the American Association of Cancer Research (AACR). The group has awarded Yibin Kang, PhD, a cancer researcher in the Department of Molecular Biology at Princeton University, its Award for Outstanding Achievement in Cancer Research. The award goes to investigators younger than 40 to recognize meritorious achievements in cancer research.
We’re particularly proud here at ACS, as Dr. Kang is an ACS-funded researcher. In fact, as Yibin often tells people, his grant from us was the first he ever submitted, back in 2004. The ACS review committee immediately saw the great promise in this young investigator and the direction of his work. He received a substantial multi-year Research Scholar Grant to investigate the functional genomics of breast cancer progression.
That’s a testament not only to the work of the ACS’s research grants program, including the committee that reviewed and funded that grant, but also reminds those who donate to the American Cancer Society how critical their support is, especially in these days of dwindling resources. We simply could not fund investigators like Dr. Kang without support from the public.
William (Bill) Phelps one of our scientific program directors, oversaw that first grant.
“Yibin is a true rising star in cancer research, and also happens to be an exceptionally good person whom I’ve been fortunate enough to get to know these past few years. The work he’s doing is nothing short of spectacular and is very likely to translate to clinical trials for treatment and/or prevention of bone metastasis. I expect some of the work that’s further along to move into clinical trials within in the next 3 to 4 years.”
Dr. Kang is not only doing groundbreaking research, he’s becoming a vocal advocate for research funding. You can read his passionate plea for continued support in a recent guest post in the New Jersey Star Ledger’s blog.